

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CT Vision (International) Holdings Limited

中天宏信(國際)控股有限公司

(formerly known as CT Vision S.L. (International) Holdings Limited)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 994)

**(1) CHANGE OF DIRECTORS; AND
(2) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

(I) CHANGE OF DIRECTORS

The Board hereby announces that, with effect from 8 May 2026, Dr. Yang Sen has been appointed as an independent non-executive Director, and Dr. Tang Dajie has resigned as an independent non-executive Director.

(II) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board hereby announces that, with effect from 8 May 2026, the composition of the Board committees has been changed as follows:

(A) Audit Committee

- (i) Dr. Yang has been appointed as a member of the Audit Committee;
and
- (ii) Dr. Tang has resigned as a member of the Audit Committee.

(B) Remuneration Committee

- (i) Dr. Yang has been appointed as a member of the Remuneration Committee;
- (ii) Dr. Tang has resigned as a member of the Remuneration Committee; and
- (iii) Mr. Wu Rui has resigned as a member of the Remuneration Committee.

(C) Nomination Committee

- (iv) Dr. Yang has been appointed as a chairman of the Nomination Committee; and
- (v) Dr. Tang has resigned as a chairman of the Nomination Committee.

(I) CHANGE OF DIRECTORS

(A) Appointment of Director

The board (the “**Board**”) of directors (the “**Director(s)**”) of CT Vision (International) Holdings Limited (the “**Company**”) and its subsidiaries (together the “**Group**”) hereby announces that, with effect from 8 May 2026, Dr. Yang Sen (“**Dr. Yang**”) has been appointed as an independent non-executive Director. The biographical details of Dr. Yang are set out below:

Dr. Yang, aged 38, obtained a Master’s degree in Management from Glyndŵr University in 2013, and was awarded a PhD in Business and Management by Bangor University in 2025. Dr. Yang has extensive experience in cross-border strategic management and investment in the technology industry, particularly in the artificial intelligence and green energy technology sectors.

Dr. Yang has previously held investor or senior management positions at a number of overseas technology enterprises, across the fields of green energy, natural sunlight technology and artificial intelligence software. He founded Tasktag Global Limited in 2016 and serves as its Chief Executive Officer, leading the development of AI-powered intelligent retrieval products built on large language models. Dr. Yang has been a consultant for China Development at the University of Chester since 2018, and he concurrently served as Director and Lecturer in Entrepreneurship & International Business Development at the same university from 2020 to 2021. Dr. Yang has served as a director and shareholder of Parans Sunlight Technology (Qingdao) Co., Ltd. since 2024. He is the international strategic development advisor to a number of technology enterprises, including Guangzhou Anyka Microelectronics Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 688620), among others.

Dr. Yang has confirmed that (a) he meets the independence as regards to each of the factors contained in Rules 3.13(1) to (8) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); (b) he has no past or present financial or other interest in the business of the Company or its subsidiaries nor any connection with any core connected persons (having the meaning as defined under the Listing Rules) of the Company; and (c) there are no other factors that may affect his independence at the time of his appointment.

Dr. Yang entered into an letter of appointment with the Company for an initial term of three years commencing from 8 May 2026 as an independent non-executive Director. He will be entitled to terminate his appointment at any time by giving the Company one month’s notice in writing. Dr. Yang will receive nil remuneration for his appointment, which is determined after Dr. Yang’s discussion with the remuneration committee of the Company and approval of the Board. Pursuant to the articles of association of the Company (the “**Articles of Association**”), the term of office of Dr. Yang as an independent non-executive Director will expire at the next annual general meeting of the Company, and he will be eligible for re-election. Thereafter, he will be subject to retirement by rotation and re-election at general meetings of the Company in accordance with the Articles of Association.

As at the date of this announcement, Dr. Yang (i) does not hold any other position within the Group and does not have any other major appointments or professional qualifications; (ii) does not have any relationship with any Director, senior management, substantial or controlling shareholder of the Company; (iii) has not held any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years immediately preceding the date of this announcement; and (iv) does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Save as disclosed herein, the Board is not aware of any matter in relation to the appointment of Dr. Yang that needs to be brought to the attention of the Stock Exchange or the Shareholders of the Company (the “**Shareholders**”) nor any information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to extend a warm welcome to Dr. Yang to join the Board.

(B) Resignation of Director

The Board further announces that, with effect from 8 May 2026, Dr. Tang Dajie (“**Dr. Tang**”) has resigned as an independent non-executive Director due to other business commitments. Dr. Tang has confirmed that he has no disagreement with the Board and that there is no matter in relation to his resignation that needs to be brought to the attention of the Stock Exchange or the Shareholders.

The Board would like to express its sincere gratitude to Dr. Tang for his valuable contributions to the Company during her tenure of service.

(II) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board hereby announces that with effect from 8 May 2026, the composition of the Board committees has been changed as follows:

(A) Audit Committee

- (i) Dr. Yang has been appointed as a member of the audit committee of the Company (the “**Audit Committee**”); and
- (ii) Dr. Tang has ceased to be a member of the Audit Committee.

(B) Remuneration Committee

- (i) Dr. Yang has been appointed as a member of the Remuneration Committee;
- (ii) Dr. Tang has ceased to be a member of the Remuneration Committee; and
- (iii) Mr. Wu Rui has ceased to be a member of the Remuneration Committee.

(C) Nomination Committee

- (i) Dr. Yang has been appointed as a chairman of the Nomination Committee; and
- (ii) Dr. Tang has ceased to be a chairman of the Nomination Committee.

By order of the Board
CT Vision (International) Holdings Limited
Sun Dexin
Executive Director

Hong Kong, 8 May 2026

As at the date of this announcement, the Board comprises five executive Directors, namely Mr. Wu Rui, Mr. Guo Jianfeng, Mr. Ding Ji, Mr. Sun Dexin and Mr. Lian Mingcheng, one non-executive Director, namely Dr. Ho Chun Kit Gregory, and three independent non-executive Directors, namely Dr. Lin Tat Pang, Dr. Yang Sen and Ms. Liu Zhen.